Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-02-23

FDA Approved: SYNTHROID — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a labeling supplement for Synthroid (levothyroxine sodium) submitted by AbbVie, updating the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SYNTHROID (LEVOTHYROXINE SODIUM)

Snippet

SUPPL AP for SYNTHROID (LEVOTHYROXINE SODIUM)